- Home
- BSLK vs RLMD Comparison
BSLK vs RLMD Comparison
Compare BSLK & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BSLK
- RLMD
- Stock Information
- Founded
- BSLK 2009
- RLMD 2004
- Country
- BSLK United States
- RLMD United States
- Employees
- BSLK N/A
- RLMD N/A
- Industry
- BSLK
- RLMD Biotechnology: Pharmaceutical Preparations
- Sector
- BSLK
- RLMD Health Care
- Exchange
- BSLK NYSE
- RLMD Nasdaq
- Market Cap
- BSLK 10.3M
- RLMD 11.5M
- IPO Year
- BSLK N/A
- RLMD N/A
- Fundamental
- Price
- BSLK $0.47
- RLMD $0.30
- Analyst Decision
- BSLK
- RLMD Hold
- Analyst Count
- BSLK 0
- RLMD 4
- Target Price
- BSLK N/A
- RLMD $4.25
- AVG Volume (30 Days)
- BSLK 17.2M
- RLMD 2.1M
- Earning Date
- BSLK 03-07-2025
- RLMD 03-18-2025
- Dividend Yield
- BSLK N/A
- RLMD N/A
- EPS Growth
- BSLK N/A
- RLMD N/A
- EPS
- BSLK N/A
- RLMD N/A
- Revenue
- BSLK $1,489,000.00
- RLMD N/A
- Revenue This Year
- BSLK N/A
- RLMD N/A
- Revenue Next Year
- BSLK N/A
- RLMD N/A
- P/E Ratio
- BSLK $0.11
- RLMD N/A
- Revenue Growth
- BSLK N/A
- RLMD N/A
- 52 Week Low
- BSLK $0.23
- RLMD $0.28
- 52 Week High
- BSLK $17.02
- RLMD $7.22
- Technical
- Relative Strength Index (RSI)
- BSLK N/A
- RLMD 30.81
- Support Level
- BSLK N/A
- RLMD $0.28
- Resistance Level
- BSLK N/A
- RLMD $0.36
- Average True Range (ATR)
- BSLK 0.00
- RLMD 0.04
- MACD
- BSLK 0.00
- RLMD 0.02
- Stochastic Oscillator
- BSLK 0.00
- RLMD 7.21
About BSLK BOLT PROJECTS HOLDINGS INC
Bolt Projects Holdings Inc formerly Golden Arrow Merger Corp is an shell company.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.